JAMA Network
About The Study: In this systematic review and meta-analysis of 18 trials, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly improved glycemic, weight, and cardiometabolic outcomes in children and adolescents with type 2 diabetes or obesity. Available data over a relatively short follow-up suggested suicidal ideation or behaviors were not significantly different, although gastrointestinal adverse effects warrant attention in long-term management.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
